510(k) device
Xpert TV
Cepheid · Trichomonas Vaginalis Nucleic Acid Amplification Test System (OUY, Class II) · First FDA decision Oct 16, 2015, newest Aug 29, 2016HIV, hepatitis and sexually transmitted infections
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "Xpert TV"
MAUDE reports
0
Brand "Xpert TV", since 2015
PubMed studies
7
Mentioning "Xpert TV"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Xpert TV
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K161619 · Decided Aug 29, 2016 · 77 days after receipt
Device type: Trichomonas Vaginalis Nucleic Acid Amplification Test System (OUY) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38227First Coast Service Options, Inc.Updated Oct 20, 2023
- Gastrointestinal Pathogen (GIP) Panels Utilizing Multiplex Nucleic Acid Amplification Techniques (NAATs)Local determinationIn effectL38229Novitas Solutions, Inc.Updated Oct 20, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Xpert TV", any status and sponsor, newest update first.
No registered device study names "Xpert TV".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Xpert TV", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OUY
30 reports: 25 malfunction, 5 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Xpert TV"[tiab]. The summary above synthesizes these.
- Aetiological testing compared with syndromic management for sexually transmitted infections in HIV-infected pregnant women in South Africa: a non-randomised prospective cohort study.
Peters R, Klausner JD, de Vos L, et al. · BJOG · 2021Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Quality control and external quality assessment for the independent clinic-based evaluation of point-of-care testing to detect Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in eight countries.
Shephard M, Matthews S, Andrewartha K, et al. · BMC Infect Dis · 2024
- WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances.
Jacobsson S, Boiko I, Golparian D, et al. · APMIS · 2018Validation Study
- Standardised protocol for a prospective international multicentre clinical-based evaluation of point-of-care tests for the screening of genital and extragenital chlamydial and gonococcal infections in men who have sex with men and for the screening of genital chlamydial, gonococcal and Trichomonas vaginalis infections in at risk women.
Cordioli M, Gios L, Mirandola M, et al. · BMJ Open · 2024Research Support, Non-U.S. Gov't
- Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis screening and treatment of pregnant women in Port-au-Prince, Haiti.
Bristow CC, Mathelier P, Ocheretina O, et al. · Int J STD AIDS · 2017
- Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women.
Schwebke JR, Gaydos CA, Davis T, et al. · J Clin Microbiol · 2018Evaluation Study, Multicenter Study
- Loop mediated isothermal amplification assay for detection of Trichomonas vaginalis in vaginal swabs among symptomatic women from North India.
Khurana S, Dadwal R, Sharma N, et al. · Lett Appl Microbiol · 2020Comparative Study
Other devices of this type
Also filed under product code OUY.
- Aptima Trichomonas Vaginalis Assay - PantherGen-Probe, Inc. · De Novo 2013
- Aptima Trichomonas vaginalis AssayHologic, Inc. · 510(k) 2023
- BD MAX CTGCTV2, BD MAX SystemBecton, Dickinson and Company · 510(k) 2019
- Bd Max Ct/Gc/Tv, Bd Max InstrumentBecton, Dickinson and Company · 510(k) 2016
- Solana Trichomonas AssayQuidel Corporation · 510(k) 2016
- AmpliVue Trichomonas AssayQuidel Corporation · 510(k) 2015
- Bd Probetec Trichomonas Vaginalis (Tv) Qx Amplified Dna AssayBecton, Dickinson & CO · 510(k) 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.